

Freedom of Information Act 2000 - Request Reference FoI/23/525

Breast Cancer Treatment

Information Requested:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor* or Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab +Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- TK Inhibitors (Neratinib/Lapatinib)
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor* or Fulvestrant
- Pembrolizumab
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor* or Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Taxane and/or Anthracycline in combination
- Trastuzumab as a single agent or in combination
- Trastuzumab conjugates (Trastuzumab emtansine, Trastuzumab deruxtecan)
- Any other active systemic anti-cancer therapy

* aromatase Inhibitors include anastrozole, exemestane and letrozole)

Response Details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. However, according to our duty to advise and assist under section 16 of the Freedom of Information Act 2000, the UHB can refer you to the following link: [Freedom of Information request - Velindre](#)

You may also find the following email address of use: FOI.VUNHST@wales.nhs.uk